Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE-MS
NCT06847724Phase 3Active, not recruiting
- Sponsor
- Sandoz
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of CYB704 in multiple sclerosis (MS), sponsored by Sandoz. Started Jun 2025; status: active, not recruiting.
02
Drugs
CYB704
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06847724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06847724.